Highlights

• Cynata has received a Notice of Allowance from the US Patent Office for its Novel MSC Manufacturing Technology.
• The patent protects the proprietary Cymerus technology up to 2037 and beyond in the USA.
• Cynata expects the patent to be granted around February 2023 with an expiration date of 15 November 2037.

Cynata Therapeutics (ASX:CYP) has provided a positive update regarding an important addition to its portfolio of Intellectual Property (IP). The clinical-stage regenerative medicine company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The allowance is for a patent application entitled “Pluripotent Stem Cell Assay”. This follows similar achievements for the Company earlier this year.

Cynata states that the patent provides further protection for its proprietary Cymerus technology up to 2037 and beyond in the USA, a major commercial jurisdiction. The patent application, which is wholly owned by Cynata covers its proprietary Cymerus™ mesenchymal stem cell (MSC) platform technology. It describes a novel method for ensuring the quality and purity of Cynata’s finished therapeutic MSC products.

What are mesenchymal stem cells (MSCs)?

MSCs are adult stem cells found in different kinds of human tissues such as bone marrow, adipose tissue (fat), placenta and umbilical cord blood. They can produce more than one type of cell and differentiate into cartilage, bone, and fat cells.

MSCs are the most widely studied type of adult stem cells and have huge therapeutic potential for several unmet medical needs. Over 1,100 clinical trials involving MSCs have been registered around the world.

Cynata’s Cymerus™ technology addresses the many challenges and complications of manufacturing MSCs at a commercial scale. It has a distinctive capability to generate highly consistent MSCs at scale, from a single donation, to develop therapeutic stem cell products.

Protection till 2037

The USPTO sends a Notice of Allowance to an applicant when it intends to issue a patent. The patent adds to the existing broad IP protection of the Cymerus manufacturing platform.

Cynata expects the patent to be granted around February 2023 and expire on 15 November 2037.

Image: © 2022 Kalkine Media®

In October, Cynata received a Notice of Acceptance from IP Australia and CIPO for its patent application entitled “Colony Forming Medium and Use Thereof”, also covering the Company’s proprietary Cymerus MSC technology.

At the time of writing this article, share price of Cynata was AU$0.300 apiece.